Bronx Prevention Center

ICAP’s two research centers in New York, the Bronx Prevention Center and the Harlem Prevention Center, are hubs of research in New York City that have been historically underserved and disproportionately impacted by the HIV epidemic and, more recently, the COVID-19 epidemic. ICAP works with local community-based organizations, religious leaders, and advocates to promote community awareness of and engagement with the research studies.

Led by Wafaa El-Sadr, MD, MPH, MPA and Jessica Justman, MD, this work is supported through the ICAP at Columbia University Clinical Trials Unit (CTU). The ICAP CTU aims to support the design and implementation of research to address gaps in the global HIV response, including through clinical research sites in the Harlem, Bronx, and Eswatini.

The Community Advisory Board (CAB) for the ICAP Clinical Trials Unit (CTU) provides guidance and feedback on proposed studies, outreach strategies, feedback on study materials, and information regarding community perceptions of the potential or current research studies.

Current studies include investigations of antibody-mediated prevention using broadly neutralizing antibodies (bnAbs) to prevent HIV or COVID-19, an injectable long-acting pre-exposure prophylaxis (PrEP) option, mobile technologies to improve PrEP adherence, integrated care for people who inject opiates, HIV vaccine studies, and studies of COVID-19 immunity, vaccine efficacy, and treatment among others.

Through Columbia University, ICAP also supports additional COVID-19 surveys and various student fellowship programs, engaging students to participate in the design, implementation, and evaluation of ICAP-supported programs while working side-by-side with its experts.


Current BPC Studies

ACTIV-2/A5401: The ACTIV StudyDistricts (or national)Bronx

CoVPN 3002: The AstraZeneca StudyDistricts (or national)Bronx

HPTN 094: The INTEGRA StudyDistricts (or national)Bronx

HTPN 083: Give PrEP a ShotDistricts (or national)Bronx

IMPOWER-022: The Merck StudyDistricts (or national)Bronx

Making PrEP SmartDistricts (or national)Bronx

Soon to Launch

PURPOSE 3/HPTN 102 StudyDistricts (or national)Bronx

Completed BPC Studies

CoVPN 5002: The COMPASS StudyDistricts (or national)Bronx

HPTN 076: Phase II Safety and Acceptability of Injectible Rilpivirine for PrEPDistricts (or national)Bronx

HVTN 704/HPTN 085: Antibody Mediated Prevention (Amp Study)Districts (or national)Bronx

In Vivo Drug Interaction Pharmacokinetic Study of Tenofovir 1% Gel and Three Commonly Used Vaginal ProductsDistricts (or national)Bronx

MTN-014: Tenofovir Levels Following Local Application of Tenofovir Reduced-Glycerin 1% GelDistricts (or national)Bronx

ICAP in Bronx

Program Start


Key Technical Areas
  • Clinical Research and Trials
  • COVID-19 Research
  • PreP Research
Current Funders
  • National Institute of Health
    • National Institute of Allergy and Infectious Diseases (NIH/NIAID)
      Department of Health and Human Services (DHHS)
    • Family Health International (FHI)
    • Fred Hutchinson Cancer Research Center
  • AstraZeneca
  • Merck



Site Leader

Ellen Morrison, MD, MPH

Dr. Ellen Morrison is the site lead and an investigator at the Bronx Prevention Center, a clinical research site that is one of the three sites that comprise the NIH-funded ICAP at Columbia Clinical Trials Unit.  Dr. Morrison leads studies that focus on HIV prevention, including the use of pre-exposure prophylaxis and the provision of integrated services on a mobile van to engage out-of-care injection opiate users in HIV prevention and care.  In addition, a rapid pivot to address the SARS-CoV-2 pandemic has included new projects on COVID-19 vaccines, testing of monoclonal antibodies, and other COVID-19 treatment modalities.  


Jobs in the United States

For international ICAP job listings see careers at ICAPACITY